Schroder Investment Management Group Has $1.27 Million Position in Laboratory Co. of America Holdings (NYSE:LH)

Schroder Investment Management Group lessened its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 24.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,554 shares of the medical research company’s stock after selling 1,810 shares during the period. Schroder Investment Management Group’s holdings in Laboratory Co. of America were worth $1,274,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of LH. Public Sector Pension Investment Board increased its position in shares of Laboratory Co. of America by 9.2% during the third quarter. Public Sector Pension Investment Board now owns 3,572 shares of the medical research company’s stock worth $798,000 after acquiring an additional 300 shares in the last quarter. Hilltop Holdings Inc. increased its holdings in Laboratory Co. of America by 46.5% during the 3rd quarter. Hilltop Holdings Inc. now owns 1,453 shares of the medical research company’s stock worth $325,000 after purchasing an additional 461 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in Laboratory Co. of America by 108.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 5,016 shares of the medical research company’s stock worth $1,121,000 after purchasing an additional 2,613 shares in the last quarter. Royal London Asset Management Ltd. raised its stake in shares of Laboratory Co. of America by 4.3% in the 3rd quarter. Royal London Asset Management Ltd. now owns 34,593 shares of the medical research company’s stock valued at $7,731,000 after purchasing an additional 1,437 shares during the period. Finally, Quarry LP bought a new stake in shares of Laboratory Co. of America in the third quarter valued at about $93,000. 95.94% of the stock is owned by institutional investors.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Amy B. Summy sold 758 shares of the company’s stock in a transaction on Friday, March 28th. The stock was sold at an average price of $231.67, for a total value of $175,605.86. Following the transaction, the executive vice president now directly owns 5,302 shares of the company’s stock, valued at $1,228,314.34. This represents a 12.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Adam H. Schechter sold 6,121 shares of Laboratory Co. of America stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total value of $1,497,319.02. Following the sale, the chief executive officer now directly owns 86,445 shares of the company’s stock, valued at $21,146,175.90. This represents a 6.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,258 shares of company stock valued at $3,753,177 in the last three months. 0.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

LH has been the topic of a number of recent research reports. Bank of America lifted their target price on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Barclays lowered their price objective on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. Evercore ISI upgraded shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. StockNews.com upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Sunday. Finally, Morgan Stanley raised their price objective on Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $270.38.

Laboratory Co. of America Price Performance

NYSE:LH opened at $222.49 on Monday. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59. The firm has a market capitalization of $18.62 billion, a price-to-earnings ratio of 25.23, a P/E/G ratio of 1.71 and a beta of 1.12. The stock’s 50 day moving average price is $243.63 and its two-hundred day moving average price is $234.95. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Thursday, February 27th were paid a $0.72 dividend. The ex-dividend date was Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.29%. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 32.65%.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.